Navigation Links
InterMune to Release Third Quarter Financial Results on November 3
Date:10/27/2011

BRISBANE, Calif., Oct. 27, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2011 financial results at the close of the U.S. markets on Thursday, November 3, 2011.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 22885421.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 22885421.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
2. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
3. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
4. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune Reports Third Quarter 2010 Financial Results
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. InterMune to Release Second Quarter Financial Results on July 27
9. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
10. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
11. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... LEBANON, N.H. , March 24, 2017 ... as the recipient of an award including funding and ... free blood draw technology.  "Making blood ... way to making their whole hospital experience better.  We,re ... how this technology can help improve care for the ...
(Date:3/24/2017)... , Mar. 24, 2017 Research ... Management in the U.S.: Consumer Strategies" report to their ... ... how adults approach and treat their physical pain, emphasizing consumer ... distinct groups: pain sufferers and adults who have selected illnesses/conditions ...
(Date:3/24/2017)... ShangPharma, a leading life science ... development and discovery services, technology, and investment ... today the intent for a strategic corporate ... the Contract Research Organizations (CRO) and Contract ... entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... ... , ... “End Time GPS”: a dauntless and enlightened study of the ... is the creation of published author, Wesley Gerboth, a World War II veteran, with ... projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him in ...
(Date:3/23/2017)... ... , ... A recent report from the National Council on Teacher Quality (NCTQ) ... suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions in ... It argues that this higher bar should be set by states, by the Council ...
(Date:3/23/2017)... ... 2017 , ... The IoT (Internet of Things) is revolutionizing the way the ... on businesses and individual consumers alike. Laboratories can maximize their profit margin by ... from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the ...
Breaking Medicine News(10 mins):